Treatment of Pediatric Acute Lymphoblastic Leukemia

Overview of attention for article published in Pediatric clinics of North America, October 2014

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#16 of 1,242)
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news: 16 news outlets
policy: 2 policy sources

twitter: 2 X users
patent: 1 patent

Citations

dimensions_citation: 250 Dimensions

Readers on

mendeley: 593 Mendeley

Summary News Policy documents X Patents Dimensions citations

So far, Altmetric has seen 2 policy documents that reference this research output.

Blinatumomab (Blincyto) for Acute Lymphoblastic Leukemia (pediatric) – Details

Cited by Canadian Agency for Drugs and Technologies in Health on 01 Jun 2023

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years : Committee papers

Cited by National Institute for Health and Care Excellence on 08 Nov 2018

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.